Company intelligence / Profile preview

BELLUS Health Inc.

Laval, Quebec, Canadagsk.com ↗

Ownership: Private
Development stage: Phase 3

Overview

BELLUS Health developed camlipixant (BLU‑5937), a highly selective oral small-molecule antagonist of the P2X3 receptor for refractory chronic cough. The SOOTHE phase IIb trial met its primary endpoint for efficacy and safety. Based on these results, the CALM phase III program was initiated with data expected in late 2024 and into 2025. A once-daily formulation entered phase I testing. The company was acquired by GSK in June 2023 to strengthen GSK’s respiratory pipeline.

Therapeutic areas: PulmonologyDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

camlipixant

Phase 3

Indications: Refractory chronic cough

Partnerships

NEOMED Institute for development/commercialization collaboration/licensing around BLU‑5937/camlipixant

Beyond the preview

Go deeper on BELLUS Health Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BELLUS Health Inc..

Explore the full profile